-- Dr. Dansey, Seagen's Chief Medical Officer, brings extensive expertise in 
immuno-oncology and drug development 

-- Appointment of industry leader in drug development expands the Board's 
diverse industry, clinical development, research and commercialization 
expertise 

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market 
precisely designed DNA medicines to treat and protect people from infectious 
diseases, cancer, and HPV-associated diseases, today announced the appointment 
of Roger D. Dansey, M.D. to its Board of Directors. The appointment adds 
extensive expertise in drug development to the INOVIO Board as the company 
strengthens its focus on its late stage product development programs. Currently 
the Chief Medical Officer at Seagen (formerly Seattle Genetics), Dr. Dansey has 
played a central role in Seagen's efforts to become a globally recognized, 
multi--product oncology company. 

Dr. Dansey previously served as the Therapeutic Area Head for Late-Stage 
Oncology at Merck & Co., Inc., where he oversaw registration efforts for 
Keytruda(R) (pembrolizumab) across multiple tumor types. Earlier in his career, 
he was the Vice President of Oncology Clinical Research at Gilead Sciences and 
the Global Development Lead for Xgeva(R) (denosumab) at Amgen, where he held 
multiple roles in both oncology and hematology. Dr. Dansey holds an M.D. from 
the University of Witwatersrand in Johannesburg, South Africa.

Simon X. Benito, Chairman of INOVIO's Board, said, "We are pleased to welcome 
Dr. Dansey to INOVIO's Board of Directors. His impressive efforts at Seagen 
coupled with his track record of achievement in cancer drug development at 
Merck, Gilead, and Amgen will be invaluable to the organization as the company 
evolves its oncology, HPV and vaccine portfolio – including INO-5401, its DNA 
medicine for Glioblastoma Multiforme (GBM) and INO-4800 for COVID-19 – and 
prepare for commercialization."

Dr. Dansey said, "I'm pleased to join INOVIO at a pivotal time for the company. 
This is the time for DNA medicines. I believe they offer an innovative approach 
to fighting cancer. I am looking forward to working with the team and 
supporting their mission of rapidly bringing to market life-saving DNA 
medicines to meet urgent global health needs in oncology and infectious 
diseases."

About INOVIO's DNA Medicines Platform

INOVIO has 15 DNA medicine clinical programs currently in development focused 
on HPV-associated diseases, cancer, and infectious diseases, including 
coronaviruses associated with MERS and COVID-19 diseases being developed under 
grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the 
U.S. Department of Defense. DNA medicines are composed of optimized DNA 
plasmids, which are small circles of double-stranded DNA that are synthesized 
or reorganized by a computer sequencing technology and designed to produce a 
specific immune response in the body.

INOVIO's DNA medicines deliver optimized plasmids directly into cells 
intramuscularly or intradermally using INOVIO's proprietary hand-held smart 
device called CELLECTRA(R). The CELLECTRA(R) device uses a brief electrical 
pulse to reversibly open small pores in the cell to allow the plasmids to 
enter, overcoming a key limitation of other DNA and other nucleic acid 
approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the 
cell to produce the targeted antigen. The antigen is processed naturally in the 
cell and triggers the desired T cell and antibody mediated immune responses. 
Administration with the CELLECTRA(R) device ensures that the DNA medicine is 
efficiently delivered directly into the body's cells, where it can go to work 
to drive an immune response. INOVIO's DNA medicines do not interfere with or 
change in any way an individual's own DNA. The advantages of INOVIO's DNA 
medicine platform are how fast DNA medicines can be designed and manufactured; 
the stability of the products, which do not require freezing in storage and 
transport; and the robust immune response, safety profile, and tolerability 
that have been observed in clinical trials.

With more than 3,000 patients receiving INOVIO investigational DNA medicines in 
more than 7,000 applications across a range of clinical trials, INOVIO has a 
strong track record of rapidly generating DNA medicine candidates with 
potential to meet urgent global health needs.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market 
precisely designed DNA medicines to treat and protect people from infectious 
diseases, cancer, and diseases associated with HPV. INOVIO is the first and 
only company to have clinically demonstrated that a DNA medicine can be 
delivered directly into cells in the body via a proprietary smart device to 
produce a robust and tolerable immune response. Specifically, INOVIO's lead 
candidate VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a 
Phase 3 clinical trial, REVEAL 1, for the treatment of precancerous cervical 
dysplasia caused by HPV-16 and/or HPV-18. VGX-3100 also demonstrated positive 
Phase 2 efficacy results in separate trials evaluating the treatment of 
precancerous vulvar dysplasia and anal dysplasia. Also in development are 
programs targeting HPV-related cancers and a rare HPV-related disease, 
recurrent respiratory papillomatosis (RRP); non-HPV-related cancers 
glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded 
infectious disease DNA vaccine development programs in Zika, Lassa fever, 
Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. 
Partners and collaborators include Advaccine, ApolloBio Corporation, 
AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic 
Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency 
(DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological 
and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines 
Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, 
Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National 
Institutes of Health, National Institute of Allergy and Infectious Diseases, 
Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline 
Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, 
University of Pennsylvania, Walter Reed Army Institute of Research, and The 
Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards "W" 
designation recognizing companies with more than 20% women on their board of 
directors. For more information, visit www.inovio.com.

CONTACTS:

Media: Jeff Richardson, +1 267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, +1 484-362-0076, ben.matone@inovio.com

This press release contains certain forward-looking statements relating to our 
business, including our plans to develop and commercialize DNA medicines, our 
expectations regarding our research and development programs, including the 
planned initiation and conduct of preclinical studies and clinical trials and 
the availability and timing of data from those studies and trials, and our 
ability to successfully manufacture and produce large quantities of our product 
candidates if they receive regulatory approval. Actual events or results may 
differ from the expectations set forth herein as a result of a number of 
factors, including uncertainties inherent in pre-clinical studies, clinical 
trials, product development programs and commercialization activities and 
outcomes, our ability to secure sufficient manufacturing capacity to mass 
produce our product candidates, the availability of funding to support 
continuing research and studies in an effort to prove safety and efficacy of 
electroporation technology as a delivery mechanism or develop viable DNA 
medicines, our ability to support our pipeline of DNA medicine products, the 
ability of our collaborators to attain development and commercial milestones 
for products we license and product sales that will enable us to receive future 
payments and royalties, the adequacy of our capital resources, the availability 
or potential availability of alternative therapies or treatments for the 
conditions targeted by us or collaborators, including alternatives that may be 
more efficacious or cost effective than any therapy or treatment that we and 
our collaborators hope to develop, issues involving product liability, issues 
involving patents and whether they or licenses to them will provide us with 
meaningful protection from others using the covered technologies, whether such 
proprietary rights are enforceable or defensible or infringe or allegedly 
infringe on rights of others or can withstand claims of invalidity and whether 
we can finance or devote other significant resources that may be necessary to 
prosecute, protect or defend them, the level of corporate expenditures, 
assessments of our technology by potential corporate or other partners or 
collaborators, capital market conditions, the impact of government healthcare 
proposals and other factors set forth in our Annual Report on Form 10-K for the 
year ended December 31, 2020, our Quarterly Report on Form 10-Q for the quarter 
ended March 31, 2021 and other filings we make from time to time with the 
Securities and Exchange Commission. There can be no assurance that any product 
candidate in our pipeline will be successfully developed, manufactured or 
commercialized, that final results of clinical trials will be supportive of 
regulatory approvals required to market products, or that any of the 
forward-looking information provided herein will be proven accurate. 
Forward-looking statements speak only as of the date of this release, and we 
undertake no obligation to update or revise these statements, except as may be 
required by law.